October 11, 2019

Ryan M. Confer
Chief Financial Officer
Genprex, Inc.
1601 Trinity Street, Bldg B
Suite 3.322
Austin, TX 78712

       Re: Genprex, Inc.
           Form 10-K for the Fiscal Year Ended December 31, 2018
           Filed April 1, 2019
           Form 10-Q for the Quarterly Period Ended June 30, 2019
           Filed August 13, 2019
           File No. 001-38244

Dear Mr. Confer:

       We have reviewed your September 30, 2019 response to our comment letter
and have the
following comments. In some of our comments, we may ask you to provide us with
information
so we may better understand your disclosure.

       Please respond to these comments within ten business days by providing
the requested
information or advise us as soon as possible when you will respond. If you do
not believe our
comments apply to your facts and circumstances, please tell us why in your
response.

      After reviewing your response to these comments, we may have additional
comments. Unless we note otherwise, our references to prior comments are to
comments in our
September 17, 2019 letter.

Form 10-K for the Fiscal Year Ended December 31, 2018

Item 9A. Controls and Procedures, page 84

1.    We have considered your response to comment one and do not agree with
your conclusion
      regarding the effectiveness of disclosure controls and procedures as of
December 31,
      2018. As indicated in our original comment, we refer you to the following
statement in
      the fourth paragraph of Sections II.D of SEC Release No. 33-8238 which
states that
      "disclosure controls and procedures will include those components of
internal control over
      financial reporting that provide reasonable assurances that transactions
are recorded as
      necessary to permit preparation of the financial statements in accordance
with generally
 Ryan M. Confer
Genprex, Inc.
October 11, 2019
Page 2
         accepted accounting principles". We believe the nature of your
material weakness
         relates to an aspect of internal control over financial reporting that
is also a part of
         disclosure controls and procedures. Please amend your filings to
conclude that disclosure
         controls and procedures were not effective.

Form 10-Q for the Quarterly Period Ended June 30, 2019
Item 6. Exhibits, page 85

2.       We acknowledge your response to comment three. Please file the amended
Form 10-Qs
         for the periods ended March 31, 2019 and June 30, 2019 and include the
correct
         certifications.
      You may contact Vanessa Robertson at 202-551-3649 or Lisa Vanjoske at
202-551-
3614 with any questions.



FirstName LastNameRyan M. Confer                              Sincerely,
Comapany NameGenprex, Inc.
                                                              Division of
Corporation Finance
October 11, 2019 Page 2                                       Office of Life
Sciences
FirstName LastName